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technique has had on neuroscience, we were 
curious to know how researchers in the field 
feel the advances in optogenetic approaches 
have influenced their work, what they think 
the future holds in terms of the application 
of these techniques and what they see as the 
obstacles we need to overcome to get there. 
Toward this end, we’ve asked a number of 
scientists to share their thoughts with us in 
this Q&A. Although we weren’t able to ask 
more than a small fraction of the field, their 
answers give an exciting view of the power and 
potential of optogenetic approaches for under-
standing, and even potentially repairing, the 
nervous system.
and applied to a vast array of questions both in 
neuroscience and beyond.
In the intervening years, improvements to 
early techniques have provided the community 
with an optogenetics tool box that has opened 
the door to experiments we could have once 
only dreamed of. Controlling neuronal activity 
in real time, we now have the ability to deter-
mine causality between activity patterns in spe-
cific neuronal circuits and brain function and 
behavior, enabling researchers to definitively test 
long-held views and advance our understanding 
of brain function in both health and disease.
Anniversaries are often a time to reflect 
and, in light of the seminal influence this 
Neuroscientists have long dreamed of the ability to control neuronal activ-
ity with exquisite spatiotemporal precision. 
In this issue, we celebrate the tenth anniver-
sary of a paper published in the September 
2005 issue of Nature Neuroscience by a team 
led by Karl Deisseroth (Nat. Neurosci. 8, 
1263–1268 (2005)). In this study, the authors 
expressed a light-sensitive microbial protein, 
Channelrhodopsin-2 (ChR2), in neurons and 
showed that exposing these neurons to pulses 
of light could activate them in a temporally pre-
cise and reliable manner. In the decade since 
this paper, ‘optogenetic’ approaches have been 
widely and enthusiastically adopted by the field 
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On the anniversary of the Boyden et al. (2005) paper that introduced the use of channelrhodopsin in neurons, 
Nature Neuroscience asks selected members of the community to comment on the utility, impact and future of this 
important technique.
How do you define optogenetics?
John Huguenard: Sensitizing neurons to light, 
then manipulating neural activity in precise 
spatiotemporal patterns to answer questions 
regarding neural circuits and behavior.
Michael Häusser: There’s a broad definition 
and a narrow definition. The broad defini-
tion is rooted in etymology: any approach that 
combines optical interrogation with genetic 
targeting qualifies as ‘optogenetic’, and that 
includes the use of genetically encoded activ-
ity sensors. However, most people generally 
use the term optogenetics to mean the use of 
probes to manipulate activity, and (as is usual 
in English) usage normally wins.
Ernst Bamberg: Optogenetics is the use of 
genetically encoded light-activated proteins 
for manipulation of cells in an almost non-
invasive way by light. The most prominent 
tool is ChR2, which allows in a cell-specific 
way the activation of electrical excitable cells 
via the light-dependent depolarization. The 
combination of ChR2 with hyperpolarizing 
light-driven ion pumps such as the Cl- pump 
halorhodopsin (NphR) allows, with high tem-
poral and spatial precision, the activation or 
inactivation of neural cells in culture, tissue 
and living animals.
Richard Tsien: This 10-year celebration, well-
deserved by the authors and journal alike, 
implicitly points to a narrower definition: use 
of genetically encoded molecules to excite and 
inhibit neurons. I would prefer it to mean any 
genetically encoded tool to record or perturb 
electrical activity of neurons and other excit-
able cells. But using a broad name to identify 
a fairly specific subset of tasks was a brilliant 
stroke, nonetheless.
Dan Johnston: I suppose that the accurate 
definition would be genetically encoded opti-
cal sensors, but it is most commonly thought of 
as genetically encoded light-activated channels. 
It’s worth noting, however, and I wasn’t aware of 
it at the time I reviewed the Boyden paper, but 
there were two papers that predated this one 
that reported a genetically encoded light-acti-
vated channel: Zemelman, B.V. et al. Neuron 33, 
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clear that the technique was very robust and rep-
licable. Shortly thereafter I decided to do a post-
doc focusing on this approach, and that’s how I 
ended up at Stanford with Karl Deisseroth.
Antoine Adamantidis: At that time, I was 
finishing my PhD at the University of Liege, 
Belgium, and we were investigating the role 
of a unique popula-
tion of neurons in the 
lateral hypothalamus 
(that is, melanin- 
concentrating hor-
mone) in controlling 
‘dream sleep’. In mam-
mals, this deep sleep 
stage lasts classically 
few minutes, which made it difficult to study 
with conventional ‘low temporal’ approaches 
(pharmacology, KO, KI, etc.) without altering 
other sleep stages. Thus, when the Boyden/
Deisseroth publication came out, I thought, 
“This is it! That’s what we need!” Since I was 
joining the laboratory of Professor Luis de 
Lecea at Stanford University a few months later, 
I emailed Karl about this idea, who replied, “OK, 
let’s meet when you get here!” We did meet, 
and, together with Dr. Feng Zhang, brought it 
to brain slices and freely moving mice to publish 
the first in vivo optogenetic paper establishing 
a causal role between hypocretin/orexin cells 
and arousal (Adamantidis, A. et al., Nature 450, 
420–424 (2007)). Thus, yes, I believe this was a 
transformative technology since early on!
Thomas Insel: While everyone assumes opto-
genetics is a great technology, reviewers on NIH 
study sections in 2005 
did not embrace this 
idea. Fortunately, a 
very smart program 
officer at NIMH rec-
ognized the promise 
of this proposal. And 
soon after this first 
NIMH K award, the 
advent of the Pioneer Awards, designed for high 
risk–high reward research, gave Karl the kind 
of support needed to take this from concept to 
tool. Optogenetics was a great object lesson for 
NIH, revealing the need for mechanisms like 
the Pioneer Award that could overcome the 
conservatism of traditional peer review.
Gyuri Buzsáki: The impact of optogenetics 
was big and instantaneous. I think all ‘engi-
neer types’ immediately recognized that this 
was the method we were all waiting for. My lab 
was doing closed-loop experiments in the hip-
pocampus at that time using electrical stimula-
tion and only speculated about the possibility 
would really work in the manners that were 
promised. I thought it might have some finite 
uses, but did not imagine it would be as “revo-
lutionary” as it turned out to be.
Krishna Shenoy: I 
had the great pleasure 
of being right here at 
Stanford and know-
ing Ed and Karl for 
years, so yes, when 
their results came in 
and the paper came 
out it was clear it 
would be an enormous advance. Could I have 
predicted how revolutionary it would be? 
No, there I’m afraid I would have underesti-
mated the full extent to which it has been a 
 neuroscience-wide seismic shift!
Sheena Josselyn: I thought the data were 
interesting, but likely not replicable and defi-
nitely not generalizable. I thought optogenet-
ics would not work reliably and, even if it did, 
the technique would be so complicated as to 
be out of reach for most neuroscience labs. My 
initial impression was that optogenetics would 
be highly parameter-sensitive and would take 
lots of fiddling to get any kind of effect. I was 
definitely in the camp that didn’t think it would 
have an impact on my kind of neuroscience.
Scott Sternson: I thought that if it worked as 
advertised, then it would be exactly the tool 
that I’d been looking for since I started in neu-
roscience.
Gina Turrigiano: Intense excitement. I 
thought the work leading up to this study was 
a beautiful example of basic curiosity-driven 
research (trying to understand the basis of 
bacterial phototaxis) leading to an unantici-
pated transformative outcome.
Kay Tye: My first 
reaction was one of 
wonder and amaze-
ment. Seriously? Is 
this really possible? I 
was a junior gradu-
ate student at the 
time and it was quite 
the buzz. Many were 
skeptical and predicted it would be a fad, and I 
of course was both curious and skeptical—but 
really too naive to let my skepticism deter my 
curiosity. Pretty soon, we just tried working with 
ChR2, trying to replicate the effects seen in the 
Boyden et al. 2005 paper. It was remarkable how 
well it worked and it was exciting to get spiking 
from patching onto cells, and it quickly became 
15–22 (2002) and Zemelman, B.V. et al. Proc. 
Natl. Acad. Sci. USA 100, 1352–1357 (2003).
Mark Schnitzer: 
The term ‘optoge-
netics’ first appeared 
in 2006 in a short 
review article pub-
lished in Journal 
of Neuroscience to 
accompany a Society 
for Neuroscience 
mini-symposium that Karl Deisseroth and I 
had organized. (Deisseroth, K. et al. J. Neurosci. 
26, 10380–10386 (2006)). We considered differ-
ent options, such as ‘photogenetics’, but even-
tually settled on optogenetics as the best term 
to describe techniques that combined optical 
and genetic facets. Notably, our original intent 
was to cover both genetically targeted optical 
control and imaging under a single umbrella 
term. Nevertheless, I have subsequently always 
preferred a narrower interpretation of optoge-
netics that covers only the control approaches 
and the wonderful field that grew out of Karl’s 
seminal 2005 paper in Nature Neuroscience; 
the broader interpretation of optogenetics that 
includes imaging is so general that, in some 
respects, it can be vague. My impression is that 
a substantial majority of the usages of the term 
optogenetics in the neuroscience literature fol-
lows the narrower interpretation.
Rachel Wilson: I think of optogenetic tools as 
a set of wrenches in a larger toolkit of geneti-
cally encoded effec-
tors. This includes 
effectors activated 
by heat, as well as 
effectors activated by 
designer drugs, etc. 
Optogenetic tools are 
often the most useful 
because light can be 
modulated so rapidly and precisely. However, 
we should just reach for the tool that suits the 
job. Sometimes the old tools are best!
What was your first reaction when 
optogenetics came onto the scene 
10 years ago? Did you think it would 
have such a transformative impact on 
neuroscience?
Peter Hegemann: We were involved from the 
beginning, as we discovered the main player, 
Channelrhodopsin, but we never expected 
such an enormous impact.
Rob Malenka: I was excited about the pos-
sibilities, but was skeptical that optogenetics 
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et al. Neuron 33, 15–22 (2002)) and demon-
strated that genetically targeting the photore-
ceptor allowed one to 
control specific neu-
ronal populations. A 
paper published in 
April 2005 showed 
that optogenetic 
activation of different 
circuits in the brain 
could change specific 
aspects of an animal’s behavior (Lima, S.Q. & 
Miesenböck, G. Cell 121, 141–152 (2005)).
These precedents do not diminish the practi-
cal importance of Boyden et al. Swapping ChR2 
for the opsin used earlier (because the molecular 
identity of ChR2 was still unknown at the time) 
made optogenetics more effective and much 
simpler to use. The alignment of simplicity, ease 
of use and efficiency catalyzed the rapid spread 
of optogenetic technology throughout neuro-
science. Although I knew from the moment I 
had the original idea that optogenetics would be 
transformative, the field didn’t explode until the 
currently dominant version of the technology 
was introduced in September 2005. But it also 
took a while for the fundamental concept to sink 
in. One of the reviewers of the first optogenetics 
paper (Zemelman, B.V. et al. Neuron 33, 15–22 
(2002)) asked whether it wouldn’t be better to 
study the retina instead, “which conveniently 
has light-sensitive cells already built in.”
Georg Nagel: There are good reasons to 
argue that optogenetics came onto the scene 
before 2005. Gero 
Miesenböck pub-
lished ‘chARGe’ in 
2002 (Zemelman, 
B.V. et al. Neuron 
33, 15–22 (2002)), 
a combination of 
three proteins that 
made neurons light 
sensitive, and Kramer, Trauner and Isacoff 
applied a chemical optogenetic approach in 
2004 (Banghart, M. et al. Nat. Neurosci. 7, 
1381–1386 (2004)) to silence neurons. Current 
Biology published the first truly non-invasive 
light-manipulation of animals: C. elegans in 
2005 (Nagel, G. et al. Curr. Biol. 15, 2279–2284 
(2005)) and Drosophila in 2006 (Schroll, C. et 
al. Curr. Biol. 16, 1741–1747 (2006)).
But optogenetics is not restricted to neu-
rons, and therefore our demonstration of a 
heterologously expressed light-sensitive pro-
ton channel in 2002 (Nagel, G. et al. Science 
296, 2395–2398 (2002)), but even more so the 
strong light-induced depolarization of several 
animal cells, including human embryonic kid-
ney (HEK293) cells, via Channelrhodopsin-2 
was more than just the evident usefulness of the 
technology itself. Indeed, in my opinion, it is to 
the credit of Deisseroth and Boyden that they 
had recognized early that by freely sharing the 
reagents and methods they can make optoge-
netics as much of a basic necessity in neurosci-
ence labs as PCs, iPhones and iPads came to be 
in the lives of everyday citizens. This is a part of 
their genius that made optogenetics spread like 
wildfire. The open-source philosophy that they 
adopted stands in stark contrast to numerous 
other techniques where the developers tightly 
control all material and procedural aspects of 
their methodology for short-term gain, which 
in most, albeit not all, cases has proven to be 
a rather penny-wise, pound-foolish attitude in 
the long run.
Yukiko Goda: My first encounter with optoge-
netics and a glimpse into the future was hear-
ing a talk by Gero 
Miesenböck. It was 
so striking to see a 
fly being controlled 
like a mechanical toy 
of sorts simply with 
a beam of light. The 
visual impact was so 
strong that one could 
almost intuitively grasp the significance of 
the technology for coming years. This was in 
contrast to the knockout mouse technology. 
Although being of equal or greater importance 
in advancing broad areas of life sciences, includ-
ing neuroscience, its impact was less immediate 
and required more academic thoughts.
Christian Lüscher: I was curious, but it took 
us 2 years to get started and try ourselves. The 
issue for us was the virus that would not express 
well initially. We also played around with dif-
ferent light sources, using expensive lasers, 
until we realized that many of the cheaper 
LEDs had enough power. Once everything was 
in place, it took us another 6 months to see the 
first photocurrents… and ever since there was 
no stopping. I certainly did not foresee the full 
extent of the transformation that optogenetics 
would bring to neuroscience, but the concept 
was so clear that there was no doubt that every-
body would use the technique.
Gero Miesenböck: The timeline implied by 
your question is incorrect. Optogenetics did 
not suddenly come “onto the scene 10 years 
ago”; on the contrary, all the core concepts of 
optogenetics were established well before the 
Boyden et al. paper appeared. A paper pub-
lished in January 2002 showed that light act-
ing on an ectopically expressed opsin could 
be used to stimulate neurons (Zemelman, B.V. 
of affecting specific neuron types and possibly 
single neurons in neuronal circuits. As soon as 
we were able to affect specific neurons optoge-
netically in my lab, I gave away my two-photon 
microscope setup, as identifying and manipulat-
ing cell types combined with large-scale record-
ing of neurons became possible in the freely 
moving animal. What more can one wish for?
Richard Tsien: I was very excited about the 
experimental possibilities it opened up and 
proud of the joint accomplishment of two 
former graduate students who had worked at 
different times in my lab at Stanford.
Ivan Soltesz: I immediately knew that opto-
genetics was going to have an unprecedented 
impact on neurosci-
ence because it was a 
technology that virtu-
ally all neuroscientists 
had been waiting for, 
one way or another, 
consciously or not. I 
think that many peo-
ple had been keenly 
aware of the fundamental veracity of Francis 
Crick’s major challenge to neuroscience that he 
formulated in 1979, that is, that the path for-
ward to understanding neuronal circuits and 
the associated behaviors was through the devel-
opment of a technology that allows the selective 
in vivo control of one type of neuron without 
affecting the activity of all others. Historically, 
there is no doubt that several scientists, myself 
included, for at least a decade before the pub-
lication of the Boyden et al. paper in 2005, had 
entertained the possibility of making specific 
types of neurons light sensitive and using light 
to switch them on and off. Some tried to make 
it happen and did not really succeed, while oth-
ers did not even try; for example, when I, as a 
fresh assistant professor, had raised the possibil-
ity of optogenetics to an accomplished senior 
scientist at my institution in 1995, he rolled his 
eyes and told me that it would be impossible to 
express enough of the light-sensitive proteins to 
generate measurable photocurrents, and I had 
believed him (entirely my fault, not his). But 
the point is that optogenetics was ‘in the air’, 
something that was expected to arrive one day, 
and when it finally did, many of us instantly 
recognized its importance. However, what I, for 
one, did not expect was how incredibly fast the 
basic proof of concept was developed into a ver-
satile, easy-to-use, widely accessible technology 
that it is today. 10 years is an awfully short time, 
and if we use my personal time metric, we could 
say that it is only 2 NIH grant cycles (a cycle 
defined as a typical 5-year R01 grant). But what 
made the rise of optogenetics so fast? I believe it 
Yukiko Goda
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or Neurons for hunger and thirst transmit 
a negative-valence teaching signal from 
the Sternson lab 
(Betley, J.N. et al. 
Nature 521, 180–185 
(2015)). Papers like 
these are probing 
and discovering new 
circuits and linking 
specific cell popula-
tions to behaviors. It’s 
important to point out that the papers pushing 
the boundaries now don’t rely solely on opto-
genetics, but use it in combination with che-
mogenetics and in vivo imaging. Optogenetics 
is one (very important) tool in the toolbox for 
dissecting circuit function.
Has there been a major breakthrough 
in our fundamental understanding of 
brain function that could not have been 
possible without optogenetics?
Christof Koch: Not yet.
Michael Häusser: Many important discoveries 
have been made using optogenetics, but if one 
sets the bar high for defining a major break-
through, then the answer is “not yet.” That 
does not mean that it hasn’t illuminated almost 
every corner of neuroscience and transformed 
the way we do experiments.
Gina Turrigiano: 
I would say that to 
date the outcomes 
have been somewhat 
modest. The tech-
nology, combined 
with advances in 
molecular genetics, 
has allowed circuit-
breaking to be done more precisely than previ-
ously possible. On the other hand in my view 
many of the ‘gee wiz’ publications that get the 
media all hepped up—that is, ‘remote control 
this and that’—were pretty obvious from what 
we already knew.
John Huguenard: 
Functional stud-
ies of specific long-
range projections 
were not possible 
before. Whether the 
insights obtained are 
a breakthrough or 
not remains contro-
versial because there are challenges in relating 
mouse behavior to humans. Our studies on 
thalamocortical connectivity in the Gria4-/- 
What types of studies or approaches do 
you think represent the most effective 
usage of optogenetics in neuroscience 
research?
Gero Miesenböck: I feel that optogenetics 
is used most productively in two situations: 
when one knows very little about neural mech-
anisms and when one knows a lot. In the first 
situation, optogenetics can help identify the 
important players (much like conventional 
forward genetic screens can), and in the sec-
ond, it can be used to test hypotheses.
Kay Tye: At this point, optogenetics is just 
another tool in our arsenals that can be 
applied in conjunction with readouts for 
naturally occurring neural dynamics to test 
hypotheses about causal relationships. There 
is nothing wrong with using optogenetic 
approaches to validate long-standing hypoth-
eses, although at this point in the field, it is a 
powerful strategy for identifying completely 
novel roles for neural circuit constituents.
Silvia Arber: I think any study that makes very 
careful use of optogenetics and, in particular, 
is aware of the fact that optogenetic activation 
assesses what a neuron can do, but not what a 
neuron does do. I often compare optogenetic 
activation technology to methods removing a 
cell at early developmental stages from its con-
text in the embryo in order to challenge it to 
differentiate into something else in a dish. Also 
there, such manipulations reveal potential, but 
not the normal fate of a cell.
Jaideep Bains: Visualizing hypothalamic 
network dynamics for appetitive and con-
summatory behaviors from the Stuber lab 
(Jennings, J.H. et al. Cell 160, 516–527 (2015)) 
in 2003 (Nagel, G. et al. Proc. Natl. Acad. Sci. 
USA 100, 13940–13945 (2003)), was a demon-
stration of optogenetics.
Coming back to the question, I did not believe 
that Channelrhodopsin would have such a 
transformative impact on neuroscience, but I 
believed already in 2002 that Channelrhodopsin 
has great power and potential, therefore we 
(Ernst Bamberg, Peter Hegemann, Georg Nagel) 
applied for a patent in the EU and US before 
publication of Channelrhodopsin-1.
Roger Tsien: Certainly Francis Crick foresaw 
the transformative impact much earlier, writ-
ing “The tendency in 
neuroscience (and 
I’m hoping that this 
will change) is to say, 
‘Yes, I’d love to have 
new tools, but will 
someone else please 
develop them’?”…
“One of the next 
requirements is to be able to turn the firing 
of one or more types of neuron on or off in 
the alert animal in a rapid manner. The ideal 
signal would be light, probably at an infrared 
wavelength to allow the light to penetrate far 
enough. This seems rather far-fetched but it 
is conceivable that molecular biologists could 
engineer a particular cell type to be sensitive to 
light in this way.”
This was published in 1999 (Crick, F. Phil. 
Trans. R. Soc. Lond. B. Biol. Sci. 354, 2021–
2025 (1999)), but he had been saying more or 
less the same idea for decades until colleagues 
such as myself persuaded him to make a pub-
lishable citation.
I wrote to Peter Hegemann an e-mail explic-
itly linking the involvement of Chlamydomonas 
opsins (see Box 1).
Roger Tsien
Jaideep Bains
Gina Turrigiano
BOX 1
Date: Sun, 10 Oct 1999 22:41:11 -0700
To: peter.hegemann@biologie.uni-regensburg.de
From: “Roger Y. Tsien” <rtsien@ucsd.edu>
Subject: algal rhodopsins
Dear Professor Hegemann: I have been interested for some time in potential methods 
by which mammalian neurons might be transfected with a gene whose product would 
permit light-triggering of depolarizations and action potentials. Eventually I came 
across your outstanding pioneering work on the light-activated conductances and opsins 
of Volvox and Chlamydomonas. However, I cannot find any papers on heterologous 
expression of these opsin genes, especially in the systems more commonly used 
in electrophysiology, such as Xenopus oocytes or HEK293 cells. Has heterologous 
expression been seriously attempted? If it has, but no light-activated currents were 
detectable, is it known whether the problem was in (a) getting enough protein expressed 
on the plasma membrane, (b) incorporating retinal or (c) finding a partner channel, if 
the opsin itself proved not to be the channel?
John Huguenard
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Jaideep Bains: I think we can be more ambi-
tious with our questions.
Patricia Janak: Optogenetics has vastly 
increased the precision with which systems 
neuroscientists can 
make causal connec-
tions between a given 
circuit and a given 
behavior. It has been 
a game-changer for 
our research. We are 
in the phase where 
this precision allows 
us to take apart circuits little by little. In the 
future, we will need to use optogenetics in new 
ways, along with other approaches, to then 
determine how multiple parts of a circuit work 
together in an integrated fashion, in vivo—this 
will be a fascinating challenge!
Richard Tsien: It has greatly heightened our 
interest in attaching functions to particular cell 
types, and in moving from questions of single 
neurons to circuits. It makes it much more 
honorable to be a toolkit inventor, building 
on the precedent of Roger Tsien, Erwin Neher 
and Bert Sakmann.
Christian Lüscher: Optogenetics is the begin-
ning of causal neuroscience! For the first time 
it has become easier to manipulate the brain 
than to observe its function. I am convinced 
that if optogenetics is used carefully, it will 
help us understand how neurons generate 
behavior. This, however, will require that we 
develop new observation techniques that have 
the same spatial and temporal resolution as 
optogenetics (for example, imaging activity 
of ensembles using genetically encoded cal-
cium indicators) such that the manipulations 
can be tailored to closely mimic physiological 
neural activity.
Antonello Bonci: 
Before optogenetics, 
my laboratory used 
electrophysiology in 
combination with 
molecular and behav-
ioral approaches 
to study drug and 
reward-dependent 
synaptic plasticity, but we didn’t have any tools 
to understand which brain pathways were 
relevant to process/modulate these behav-
iors. When we started using optogenetics, we 
could finally start addressing which pathways 
matter and for which behaviors. Furthermore, 
it allowed my team to address another fun-
damental question: the relationship between 
One point that is tremendously important, 
but very difficult to quantify, is the emergence 
of a sort of can-do attitude thanks to the co-
development of optogenetics and genetic engi-
neering. No problem is too difficult to tackle, 
no mystery too opaque to be penetrated. This 
brave new attitude alone makes optogenetics, 
along with genetic engineering, an extraordi-
nary game-changer in our field.
Rob Malenka: ‘Fundamental understanding’ 
may be too strong a phrase. Optogenetics has 
certainly advanced 
our understanding 
of brain function in 
very important and 
even astounding 
ways. But it has not 
caused a true para-
digm shift (using 
the term correctly as 
Kuhn intended) in how neuroscientists think 
about brain function. We still think about 
circuits and how they function. We can just 
explore circuit function and define novel cir-
cuits in ways that we could not do and were 
in fact, unimaginable, without optogenetics.
How has the advent of optogenetics 
changed the types of scientific 
questions you ask and your approach to 
solving them?
Christof Koch: We can move from observing 
the brain to interfer-
ing in it. Given the 
sheer inexhaustible 
multiplicity of causal 
factors responsible 
for any one action in 
the nervous system, 
inferring which ones 
are actually responsi-
ble will not be easy even though we now have 
the technology.
Silvia Arber: Working on questions of motor 
control, the temporal resolution that optoge-
netics offers is very 
valuable. It is now 
possible to study at 
millisecond resolu-
tion how changing 
neuronal activity of 
defined neuronal 
populations influ-
ences motor behav-
ior. That allows us to make the link between 
genetically/developmentally defined neuronal 
populations and their precise function in an 
animal in vivo.
paper (Paz, J.T. et al. Nat. Neurosci. 14, 1167–
1173 (2011)) enabled in a way the study of Bo Li 
on selective attention. Driving of parvalbumin 
cells to produce gamma would not have been 
possible, and although predicted from earlier 
theoretical studies, this function, and the ability 
to modulate it by light, is a breakthrough.
Sheena Josselyn: At first, the studies using 
optogenetics were mostly confirmatory (veri-
fying lots of what we already knew about how 
the brain worked from decades of lesion/
pharmacology and genetic studies). I think 
this is true of most new technologies (such 
as fMRI). Scientists needed to be convinced 
that it works as advertised before they started 
thinking about how to do really interesting 
and innovative experiments to take advantage 
of the power offered by this new tool. I think 
the field has now begun to design experiments 
that take full advantage of this tool. But again, 
it is only a tool and should not be used to drive 
the experimental question.
Ann Graybiel: The use of optogenetics has 
allowed for the first time the manipulation of 
specific neural cells 
in real time in awake, 
behaving animals. 
Prior use of electri-
cal microstimulation 
allowed rapid manip-
ulation, but failed to 
allow manipulations 
with cell-type speci-
ficity. Because neurons with different func-
tional characteristics are intermixed side by 
side, manipulations without cell-type speci-
ficity could not reveal the extent of functional 
specificity of microcircuits in the mammalian 
brain. The combination, in optogenetics, of 
fast kinetics and cell-type specificity has led 
to a major breakthrough in our identification 
of, and understanding of, this feature of neural 
circuit design: within any given circuit, there is 
extraordinary cell-by-cell microcircuit speci-
ficity, whereby intermingled neurons with dif-
ferent patterns of connectivity can influence 
ongoing and future behavior in strikingly 
selective ways. Such circuit design was, of 
course, posited before, and was familiar espe-
cially to neuroscientists working on inverte-
brates, but before optogenetics, this selectivity 
could rarely be examined systematically at the 
experimental level in mammals. As an exam-
ple, this feature of optogenetics has allowed 
neuroscientists to uncover specific functions 
of interneurons never before open to experi-
mental analysis. It further has allowed the dis-
covery of a level of online control of behavior 
never before identified by previous methods. 
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Ivan Soltesz: I think it is definitely comparable. 
However, in a way, it was more useful because, 
unlike patch-clamp or MRI, optogenetics is a 
control technology that allows the investigator 
to interfere with and rationally manipulate the 
neuronal system in a causal manner in vivo, 
and not ‘just’ record/describe the activity or 
structure. Furthermore, patch-clamping and 
MRI, to remain with these specific examples, 
never really spread beyond the labs that had 
already been doing electrophysiology or imag-
ing, whereas optogenetics found applications 
in virtually all aspects of neuroscience. It is a 
very rare technology that can impact so many 
fields so fast and so thoroughly.
Sheena Josselyn: Optogenetics is right up there 
with these other transformational technologies. 
The wonderful thing about optogenetics though 
is that both labs interested in patch-clamp and 
labs interested in MRI can now incorporate 
optogenetics into their arsenal. This technique 
is agnostic to the type of question being asked. 
It can be used in slices, behaving rodents and 
non-human primates. Plus, the ease with which 
optogenetics can be set up and used makes it 
attractive to non-aficionados. I’m amazed by 
how many labs have incorporated optogenetics 
into their research without a huge investment 
in training (unlike patch-clamp) or equipment 
(unlike MRI). The way the optogenetics tools 
have been shared also makes it easy for new labs 
to use this technique. The brain, for whatever 
reason, seems highly forgiving. That is, large 
behavioral effects are observed when largely 
undefined groups of neurons are synchronously 
driven by ChR2. Although the early studies did 
not even attempt to recapitulate the precise 
temporospatial firing properties that the brain 
normally uses to communicate, nonetheless, the 
standard 20-Hz stimulation typical of the early 
experiments produced large, reliable behavioral 
responses. It’s as if this manipulation was suf-
ficient to nudge the circuits into a different state.
Thomas Insel: The importance of optogenetics 
is that it brings neuroscience closer to causal-
ity. The first 50 years of neuroscience have been 
mostly observational and correlational. Because 
optogenetics allows us to turn on and turn off 
function with cell-specific, millisecond preci-
sion, we can begin to identify the activity that 
is both necessary and sufficient to link neural 
function to behavior. There are limits, but this 
is a transformative technology for neuroscience. 
One other important insight from this technique 
is that the fundamental advance—using an 
opsin—simply borrows from an experiment of 
nature. Indeed, some of the best science of the 
last few decades has come from studies in arcane 
species where natural adaptations have revealed 
patch-clamping remains a highly specialized 
method that can only be used to address a 
very circumscribed, finite group of ques-
tions. Prior to patch clamping, we still had 
traditional intracellular recording techniques 
that worked for many of the questions that 
CNS electrophysiologists wanted to address. 
Of course, patch-clamping allowed biophysi-
cists to look at single channel properties, but 
that topic interests a small number of neuro-
scientists. In contrast, optogenetics opens up 
new types of experiments that a broad array of 
neuroscientists are interested in  performing—
ranging from hardcore cell biologists and 
electrophysiologists to behavioral neurosci-
entists working in species ranging from flies 
to monkeys. Optogenetics also has a broader 
impact on basic neuroscientists than MRI 
because MRI needs such highly specialized 
and expensive equipment and technically is 
only understood by a small group of investi-
gators. Thus, it’s accessible to a small number 
of working neuroscientists. Plus the tempo-
ral and spatial resolution of fMRI approaches 
really limit what it is able to tell investigators.
Yukiko Goda: From my perspective, optoge-
netics thus far have been powerful in charac-
terizing brain circuits at the mesoscopic scale. 
This is somewhere between MRI, which has 
been revolutionary in functional mapping of 
macroscopic brain regions, and patch-clamp 
recording technique, which has had an enor-
mous impact on neurophysiology at molecular 
and cellular levels. Not to mention, though, 
optogenetic tools have also been useful for 
addressing questions at the cellular level.
Anatol Kreitzer: Optogenetics has been the 
most influential breakthrough in neurosci-
ence during my scientific career. It is at least as 
important as any major technical development 
in the past century, including Golgi staining, 
voltage clamp, patch clamp, GFP, calcium indi-
cators and two-photon microscopy.
Richard Tsien: Interesting that you happen to 
draw comparisons with methods that are largely 
devoted to measuring 
activity rather than 
merely manipulat-
ing it. Optogenetics 
is way up there in the 
way it has captured 
the imagination of 
experts and lay pub-
lic alike. But I have 
to chuckle when newcomers think that practi-
cally every problem in neuroscience calls for an 
optogenetic approach. But no question that the 
methods are very powerful.
synaptic strength and drug-dependent and 
reward-related behaviors. Optogenetics 
offered us the opportunity of major leaps for-
ward in our understanding of these complex 
behaviors. Yet this isn’t the best part about 
optogenetics. Optogenetics allowed my lab 
to attack the most relevant question that has 
haunted me since I became a scientist: how 
to translate quickly and effectively our rodent 
studies into treatments for patients.
Jessica Cardin: The ability to manipulate tar-
geted cell classes on a fine temporal scale has 
dramatically changed the way we pose ques-
tions about network interactions. Rather than 
compiling extensive 
observations and 
making inferences 
about the impact of a 
particular cell class, 
we tend to ask the 
causal questions at 
the beginning of a 
series of experiments 
and examine both causal and observational 
data in parallel. Rapid iteration of optogenetic 
and viral tools has also led us to make fewer 
up-front assumptions about experimental 
limitations.
Michael Häusser: 
It has completely 
changed how we do 
experiments in cel-
lular and systems 
neuroscience. It has 
provided us with 
powerful tools for 
making causal links 
between elements of neural circuits and 
behavior—in that we can prove both necessity 
(by inactivating neuronal populations) and 
sufficiency (by activating the same neurons). 
It is progressively replacing conventional 
pharmacological experiments, in that now 
one can directly identify the contribution of 
a particular neurotransmitter pathway, rather 
than just the involvement of a receptor for a 
neurotransmitter. And it has meant that we 
are progressively abandoning stimulating and 
recording electrodes, the tools that I grew up 
with as an electrophysiologist.
How does the advent of optogenetics 
compare to other technological 
breakthroughs such as the patch-
clamp recording or magnetic resonance 
imaging?
Rob Malenka: I think it has had a much big-
ger impact than patch-clamping because 
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with science. Of course, a tool is never enough, 
it must be used to build understanding and/or 
build treatments.
Rui Costa: Both go 
hand in hand: the 
technology is enabling 
for the prepared 
mind. If it would have 
arrived earlier before 
optics was so easy and 
before circuit map-
ping tools and trans-
genesis and genetic tools were less developed, it 
is unclear if it would have taken off so fast. The 
field was ready and in need.
Sheena Josselyn: Both must be done in con-
cert. New tools can inspire research—reminds 
me of Maslow’s ham-
mer (that if all you 
have is a hammer 
everything starts 
looking like a nail). 
Tool development 
can allow scientists 
to ask entirely new 
questions. With the 
BRAIN initiative and similar global funding 
mechanisms, the development of tools has 
been garnering a large amount of attention 
(and resources). However, the value of a tool 
only becomes apparent when it is put to use 
in service of an important biological question.
Here’s a funny story about the subtle scien-
tific pressure to adopt the latest tools. A few 
years ago, I gave a presentation where I showed 
our labs’ data on overexpressing a transcrip-
tion factor and examining the effect on 
memory. As soon as I finished, one audience 
member’s hand shot up and the listener que-
ried the ‘non-physiological’ way in which I had 
manipulated the brain. He suggested that we 
instead use a more natural approach. Feeling 
slightly annoyed by this, I concurred that our 
manipulation was indeed non- physiological. 
What we really needed to do was to artificially 
express a protein from a bacteria in neurons 
in the brain, implant an optical fiber and then 
shine a light on these neurons. I asked my 
inquisitive colleague if this approach would 
be more physiological. He nodded his head in 
agreement. It just goes to show how the field 
has really embraced optogenetics and now 
feels it is a standard (must-use) technique.
Ernst Bamberg: This question is difficult to 
answer because, depending on the situation, 
both approaches can be helpful; in other words, 
this is not a clear alternative. I like to cite Max 
Planck: “Knowledge precedes application.” 
Anatol Kreitzer: Scientific questions should 
always be primary. If you are following tech-
nological innovation, it’s akin to the ‘streetlight 
effect’ where you are searching where it’s easi-
est (under the streetlight), but not necessar-
ily where it’s most productive (where you lost 
your keys). In the case of optogenetics, it has 
enabled a vast number of experiments that are 
yielding critical new information about brain 
function. If it enables you to address long-
standing questions, that’s great. If you want to 
use it only because it’s an exciting new tool that 
everyone is using, that is absurd.
Gyuri Buzsáki: Carl Ludwig, the inventor of 
the kymograph, advocated that “Methode is 
Alles.” While there is 
truth in this wisdom, 
the history of science 
shows that there is 
no simple recipe. For 
example, holography 
and its possible impli-
cations were outlined 
early, but practical 
applications had to wait for fast and reliable 
lasers. On the other hand, single-cell PCR and 
GFP-labeling methods fertilized thinking and 
brought about numerous discoveries not only 
not possible without them, but which were not 
even conceived before the existence of those 
methods. Just as nature exploits whatever sub-
strate or mechanism is available for novel solu-
tions, the scientific community also quickly 
jumps on novel methods because they provide 
new windows on existing  problems and new 
windows offer new views. Novel techniques 
always undergo an evolution. The initial, hyper-
enthusiastic phase is often mixed with outra-
geous claims about the novel method’s power 
and specificity. In the maturational stage, the 
claimed super-specificity and super-sensitivity 
issues are reduced and replaced by more sober 
understanding of the objective and reliable 
values of the method. In the third phase, the 
innovation is adopted by a large community 
and combined with other methods. This is 
typically the stage when major breakthroughs 
are expected. Optogenetics is currently quickly 
transitioning between the first and third stages, 
but the hard work needed for the maturation 
stage needs to be invested sooner or later as well.
Krishna Shenoy: Neuroscience tools are 
extremely important, just as in all other areas 
of science and engineering. I’m very happy that 
President Obama’s BRAIN initiative has high-
lighted the importance of this. And of course 
optogenetics is a shining (no pun intended) 
example of this. Tools can lead, tools can fol-
low and tools can be developed hand in hand 
extraordinary opportunities. Neuroscientists 
who become naturalists, poking around in the 
broad world of biology for new tools, almost 
always find something interesting.
Having witnessed the proliferation of 
optogenetics, should tools be developed 
to answer specific scientific questions, 
or should technological innovation come 
first and the scientific questions follow?
Dan Johnston: Technical innovations always 
lead the scientific questions, and this has cer-
tainly been true with optogenetics. Given the 
right tools, clever 
scientists will always 
come up with novel 
questions that can 
be answered with the 
new techniques. They 
might not have even 
thought of the ques-
tions without them.
Christof Koch: Both will happen simultane-
ously, one driving the other in a continuous 
loop.
Scott Sternson: Technology, including opto-
genetics, is developed to address a scientific 
need that is relevant to many questions. Before 
optogenetics, it was clear that approaches to 
manipulate the activity of specific neuronal 
cell types were needed, and there had been 
various attempts at this before optogenetic 
methods were achieved. Channelrhodopsin, 
in particular, turned out to be remarkably easy 
to use and was quickly adopted by neuroscien-
tists working on all types of questions.
Gero Miesenböck: The scientific question 
must always take center stage. I get dismayed 
when postdoc applicants want to join my lab 
to work on optogenetics, or when search com-
mittees approach me to suggest faculty can-
didates in optogenetics. Imagine 30 years ago 
there had been a hiring spree of faculty work-
ing on PCR. What would these people have 
been doing since then?
Yang Dan: I think 
it goes both ways, 
people are motivated 
to develop new tech-
niques when they see 
major technical road 
blocks for a particu-
lar field, but some-
times a technique 
finds surprising application in another field 
that the developer is not initially aware of.
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delivery, binding affinity, etc. Another idea that 
several groups have initiated effort toward, but 
still requires development, is the use of magne-
tism to activate genetically encodable proteins 
because it could be highly penetrant, non- 
invasive and could be relatively fast.
Peter Hegemann: In reality, light is not a good 
medium to activate proteins in large animal 
brains; light is more suitable for transparent 
model organisms like C. elegans, Drosophila 
and Zebrafish. 
What we need for mammalian brains are 
proteins that are sensitive to other media as 
ultrasound, teraherz 
radiation or mag-
netic fields that pen-
etrate the brain much 
better than light. 
What we also need is 
improved light con-
trol of DNA editing, 
gene expression and 
light-sensitive enzymes, which not elaborated 
well enough yet but bear a tremendous poten-
tial for future applications in the neurosciences 
and developmental biology.
Anatol Kreitzer: One of the biggest technical 
limitations of optogenetics is the current lack 
of tools for local control of axons and pre-
synaptic terminals. A number of questions in 
systems neuroscience necessitate the control 
of specific axonal projections (for example, 
to Region A, without affecting projections 
of axon branches from the same neuron to 
Region B). Selective activation of axons in 
Region A with channelrhodopsin yields anti-
dromic spikes that may propagate to Region B. 
Selective inhibition of axons in Region A with 
current optogenetic tools has been difficult, at 
best. Developing a tool for temporally precise 
and reversible optical control of neurotrans-
mission would be a major advance.
Botond Roska: When 
using viruses as deliv-
ery tools, there is 
a variation in the 
expression of optoge-
netic tools. This is a 
major limitation since 
it precludes quantita-
tive interpretation of 
results. Simultaneous optical actuation with 
readout and feedback could solve this problem 
in the future.
Krishna Shenoy: There is one on my mind 
much these days, and it can be overcome (we 
are working on it, together with Karl). The 
these patterns in the exact subset of neurons 
using optogenetic activation or silencing. Most 
approaches today involve synchronous acti-
vation or silencing of the neurons. Improved 
fidelity to the endogenous activity patterns 
would truly realize the potential for optoge-
netics to test the causal relationship of neuron 
activity patterns in the brain to behavior.
Gero Miesenböck: I see three principal limi-
tations. The first is the difficulty of gaining 
selective and comprehensive genetic access 
to the neurons of interest. The second is the 
difficulty of tailoring optical control signals 
to individual cells in a population rather than 
the population as a whole. This is not only a 
technical problem, but also an intellectual one. 
What types of activity pattern should we play 
back to the brain if we had the ability to do so? 
This brings me to the third, most fundamen-
tal difficulty: the lack of a theoretical under-
pinning for much of neuroscience. We don’t 
understand most neural systems well enough 
to articulate and test clear hypotheses.
Kay Tye: Right now we need to a priori know 
the genetic features and have a handle for 
expressing optogenetic tools in specific neu-
ronal populations. What we can’t really do 
yet is target cells based on specific functions. 
Although immediate early gene promoters 
have done a lot in this vein, the windows for 
tagging are still very imprecise, many orders 
of magnitude greater than the functional 
speed of information transfer in a neuron. 
Furthermore, just to say that a cell was ‘active’ 
during a window is not the same as being able 
to identify specific patterns of behavior within 
a subset of cells and label only those popula-
tions. So right now, we are not able to selec-
tively manipulate neurons with highly specific 
functionality, and we are limited by the existing 
genetic tools and/or large temporal windows 
of activity. Furthermore, selective playback of 
diverse, specific patterns across large popula-
tions of neurons also represents an ongoing 
challenge. This has been a problem that can 
be tackled in relatively small populations of 
opsin-expressing neurons with two-photon 
imaging, but there are limitations in how 
many neurons can be controlled in this man-
ner. Finally, the biggest limitation or challenge 
with optogenetics is light delivery. Light is great 
because it is temporally precise and has many 
specific wavelengths, but it does not penetrate 
through fatty tissues very well, and has been 
a challenge when translating to larger brains, 
like primates. Pharmacogenetic approaches 
address this issue, but come with the tradeoff 
of much slower timescales for onset of activa-
tion/inhibition, and these are limited by drug 
The optogenetic tool ChR was found exactly 
according to the motto by Max Planck because 
we wanted to know how this molecule works, 
which afterwards was applied to optogenet-
ics. Now optogenet-
ics opens from its 
beginning completely 
new possibilities for 
new scientific ques-
tions, which requires 
for many problems 
the development of 
appropriate tools.
Richard Tsien: I am troubled by the word 
‘should’, used twice in this sentence. If it’s 
‘should’ as in ‘ought to be’, then who gets to 
define this imperative? Funding agencies, peer 
reviewers, individual scientists or perhaps even 
the general public? Here, I prefer the possibly 
chaotic patterns of an open system, without 
too much top-down direction. Clearly, funding 
needs to be balanced for tools invented on spec 
and funding for goal-driven studies that invent 
new tools as they go along. Having spoken with 
Hodgkin and Huxley, heroes for many of us, 
after their landmark work on excitability, I feel 
strongly that there’s a lot of room for those that 
invent their own tools for biological studies and 
those that are happy to use the tools of others. 
Cole invented the voltage clamp, but Hodgkin 
and Huxley knew much better what to do with 
it. Both contributions were essential.
What do you feel are major conceptual 
and/or technical limitations in how 
optogenetics is used in the lab today?
Rob Malenka: For many uses, we’re still lim-
ited by the availability of Cre driver lines or, 
more generally, the genetic access to many 
important subsets of neurons. We’re also lim-
ited by the light-delivery systems, although 
engineers are working hard on this and I think 
it is likely that in a few years injectable LEDs 
or similar light sources that are controlled 
remotely will be available.
Scott Sternson: Optogenetics needs to be 
used primarily to assess the functional sig-
nificance of activity 
patterns measured 
in vivo during behav-
ior. Most studies 
do not do this yet, 
but, with improved 
deep-brain imaging 
capabilities, it will 
become increasingly 
common. However, even if the activity pat-
terns are known, we can seldom reproduce 
Ernst Bamberg
Scott Sternson
Botond Roska
Peter Hegemann
np
g
© 
20
15
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
1210 VOLUME 18 | NUMBER 9 | SEPTEMBER 2015  NATURE NEUROSCIENCE
Q&A
decreasing the possibility for tumor formation. 
As mentioned above, there are ongoing efforts 
to apply optogenetics in human brain tissue 
in several labs using ex vivo approaches (that 
is, resected human brain slices, either acute 
slices or organotypic slices). There are private 
companies that try to make the clinical appli-
cation a reality, fueled by venture capital (for 
example, Circuit Therapeutics). Exactly where 
(which disease) will be the one where the first 
breakthrough will occur in terms of clinical 
applications is hard to predict, but medically 
intractable focal epilepsies are definite can-
didates because, unlike in almost any other 
application involving the human brain, in the 
case of the epilepsies the viral vector could be 
injected and optogenetic control attempted in 
the specific brain area containing the seizure 
focus, which will be then surgically resected 
in any case as part of traditional ‘therapy’. 
Another area where clinical application may 
take place is pain, where there is usually a 
well-defined area where intervention can be 
attempted. Obviously, safe long-term light-
delivery devices will need to be adopted or 
developed, and most likely the first applica-
tions will be targeted at brain regions closest to 
the dura (that is, not located deep in the brain).
Roger Tsien: Once I did not think so, but my 
mind has been changed by the spectacular 
progress toward retinal prostheses such as 
from the group of Duebel in Paris.
Christian Lüscher: Yes, eventually, but not in 
the next 10 years. There are many obstacles, 
such as cell type–specific targeting, stability 
of expression, viral long-term toxicity, etc., 
that preclude translation for the moment and 
much development is required to overcome 
them. I, however, see a window to use optoge-
netics to develop new deep brain stimulation 
(DBS) protocols. Characterizing pathological 
circuit function (with optogenetics) in non-
neurodegenerative behavioral diseases may 
lead to blueprints of manipulations aiming at 
restoring normal circuit function, thus revers-
ing the pathological behavior (with optogenet-
ics). If such protocols can then be emulated 
with DBS, clinical 
trials can be envi-
sioned that test for 
safety and efficacy. 
In other words, opto-
genetically inspired 
DBS is the ‘hic et 
nunc’ translation of 
 optogenetics.
Thomas Insel: Optogenetics was one of the 
formative technologies that led to the  current 
and with enough accumulation the natural 
cellular machinery is jeopardized and cells 
may become sick. Much effort would need 
to be invested in developing and testing safer 
opsin expression strategies, and these strate-
gies would need to be tested for years or even 
decades since we understand the brain far less 
than we understand some of our peripheral 
systems. For example, using optogenetics to 
help blind people see again is in a different cat-
egory because if opsins are presented to the ret-
ina, this does not impose an added risk to the 
patient since they are already blind. However, 
if someone has a mental health problem such 
as depression, it is quite possible to impose an 
added risk as we could for example also dam-
age circuits important for cognition or sensory 
processing while trying to treat the depression.
Botond Roska: I hope so. We are working on 
it.
Anatol Kreitzer: Yes, I believe so, and we may 
see some early successful applications (for 
example, in the ret-
ina) within a decade. 
But I suspect it will 
be longer before it 
becomes a widely 
used tool for treat-
ing CNS disease. 
There are many fun-
damental questions 
that need to be addressed. Can optogenetic 
proteins be stably expressed and activated in 
human brain without inflammation or dis-
ruption of cellular processes over decades? 
How will optogenetic proteins be targeted 
and expressed in specific cells of the human 
brain? How will light be delivered uniformly 
over broad areas deep in the human brain?
Ivan Soltesz: I really think and hope so. There 
is no doubt that optogenetic-based interven-
tions do work in experimental animals in sev-
eral models of neurological and psychiatric 
disorders, and by ‘work’ I mean they do things 
that are otherwise not possible (in my field of 
closed-loop control of intractable epilepsies, 
for example, optogenetics-based intervention 
can abort a seizure in a way that interferes with 
only a minimal number and specific types of 
cells; only a few years ago, nobody thought 
that one can abort seizures after they have 
started without shocking the brain with huge 
currents). Optogenetics have also been imple-
mented in non-human primates, and there are 
clinical trials with viral vectors, for example, 
AAVs. In addition, as we understand it today, 
insertional mutagenesis may be avoided 
using vectors that remain extrachromosomal, 
major theme of understanding populations 
of individual neurons requires, we believe, a 
dynamical systems perspective that has as a 
central concept dimensionality of the neural 
data. For example, if we record from 100 neu-
rons, we often find the motor cortices only 
appear to use 10–15 dimensions (independent 
degrees of freedom; see Cunningham, J.P. & 
Yu, B.M. Nat. Neurosci. 17, 1500–1509 (2014) 
for a review). But, while optogenetics provides 
cell type–, temporal- and projection pattern–
specific activity modulation, you cannot ‘push’ 
neural activity out in certain dimensions. 
You can push activity up/down in groups of 
cells, but these cells may well (and generally 
do) contribute to multiple dimensions. So we 
need to be able to more precisely and selec-
tively manipulate specific neural dimensions 
in order to mesh with this other major thrust 
area of systems neuroscience these days. We 
think the key is, no surprise, patterned optical 
illumination so that you can more selectively 
influence specific dimensions.
Patricia Janak: Scientists need to keep in mind 
the caveats that may arise in some experimen-
tal designs as a result of synchronous optoge-
netic activation of neuronal populations in 
bulk that does not mimic natural activity of 
the neurons or projection fibers in question. 
Complementary measurements of in vivo neu-
ral activity are required to fully understand the 
natural behavior of the circuit in question.
Jaideep Bains: There are two issues that stand 
out for me. First, in vivo activation with light 
results in (potentially) non-physiological 
synchronization of neural population firing. 
Second, its use as a tool in brain slice experi-
ments to examine synaptic function is limited 
because of widespread expression in membranes 
throughout the cell that can result in recruit-
ment of calcium release from internal stores.
Do you feel that optogenetics will ever 
become a clinical tool for treating human 
disease?
Kay Tye: Regarding diseases of the brain, I 
would never say never, but there are some 
major challenges that stand in the way. First, 
light delivery represents a component that will 
very likely require it to be an invasive strat-
egy. Optimization could reduce the degree 
of invasiveness required, but that is one issue. 
Second, opsin expression is another prob-
lem. Right now, in animal research, the main 
strategy (aside from transgenic animals) is 
viral transduction. But viral vectors typically 
do not induce very stable expression, as the 
protein continues to accumulate over time 
Anatol Kreitzer
Christian Lüscher
np
g
© 
20
15
 N
at
ur
e A
m
er
ic
a,
 In
c.
 A
ll 
rig
ht
s 
re
se
rv
ed
.
NATURE NEUROSCIENCE  VOLUME 18 | NUMBER 9 | SEPTEMBER 2015 1211
Q&A
further, these technologies may also open up 
the way to use ongoing activity dynamics to 
predict future behaviors and trigger optoge-
netic interventions to modulate that future 
behavior; for example, in my own field, I 
expect to have seizure prediction-based (as 
opposed to ‘just’ seizure detection-based) 
optogenetic control of intractable epilepsies 
within the next 10 years, that is, to use activity 
dynamics that predict the future occurrence 
of the epileptic seizure to trigger the optoge-
netic intervention and prevent it from ever 
taking place. Another major breakthrough 
can be expected through the development 
of wireless communications and wireless 
powering of the electrophysiological and 
optogenetic recording and delivery devices 
in freely moving animals. There are several 
excellent bioengineering labs that are pushing 
the envelope on this key technology that will 
make the need for tethered in vivo recordings 
from behaving animals history. The need is 
clear; for example, in my lab, where we do 
24/7 video-EEG monitoring and closed-loop 
optogenetics in mice, the tethered nature of 
the recordings is a huge challenge, especially 
since the animals are having robust behavioral 
seizures, so it would be truly transformative 
to have wireless recording and light-powering 
technology that would negate the need for 
long wires and optical cables that can twist 
and break. Of course, the technology has to 
be dependable and affordable for it to have a 
significant impact.
Anatol Kreitzer: The future of systems neuro-
science is large-scale, non-invasive, all-optical 
control and recording. This will be obtained 
first in zebrafish and C. elegans, but it should 
eventually be possible within regions of the 
mammalian brain as well. It will require new 
tools and technology (next-generation voltage 
sensors, wide-field objectives, new imaging 
modalities), but it will eventually happen.
Michael Häusser: Even though optogenet-
ics has reached the status of a standard tool 
in neuroscience, being applied in thousands 
of labs world-wide, its true potential is only 
beginning to be tapped. The ability to perform 
‘all-optical’ interrogation of neural circuits 
will be truly transformational, allowing us 
to perform precisely targeted and calibrated 
interventions in the spatiotemporal dynamics 
of neural circuits on the scale of natural pat-
terns of activity, and should help us to crack 
the neural code and pinpoint how circuits are 
altered during disease.
Botond Roska: (Fortunately) One cannot pre-
dict the future.
and of course our goal now is to run studies 
on larger populations and standardize this 
treatment, in order to define how many ses-
sions are required to keep patients free from 
cocaine use. While this is the first example 
of such an optogenetic-based rTMS study, I 
predict that many more will follow, for other 
types of addiction and behavioral problems.
Michael Häusser: Absolutely. The most likely 
early prospect is for restoring vision in the 
retina, which is, after all, the most accessible 
part of the brain.
Where do you see the use of optogenetics 
heading in the next 10 years?
Dan Johnston: I would love to see optogenet-
ics extended to other channels, ones that don’t 
just fire or silence cells, but those that have 
more subtle effects. This could be used as a 
form of light-activated pharmacology.
Ernst Bamberg: A growing number of 
optogenetic tools are available. Not only 
 rhodopsin-based tools exist, but also other 
light receptors such as light-activated cyclases 
are under study. Still, the main problem is 
the precise cell-specific expression in living 
animals. It would be of great interest for cell 
biologists if these tools could be expressed 
also in cell organelles. In other words, the 
major limitation is the lack of appropriate 
molecular biology.
Gyuri Buzsáki: Methods for interacting with 
brain circuits at the single-neuron, single-
spike level are within reach. Only with such 
high temporal and spatial resolution tech-
niques will it become possible to ‘implant’ 
physiologically relevant synthetic patterns into 
brain circuits and verify hypotheses based on 
correlational observations.
Ivan Soltesz: I think that a major break-
through that will take place will have to do 
with a much-increased availability of truly 
cell type–specific genetic lines and viral vec-
tors for opsin expression for which currently 
there are no good single genetic markers, 
through either intersectional optogenetics or 
some other new ways. Ways to control cells 
based on their specific developmental origin 
are also going to be increasingly important, 
and so will the optical control of gene expres-
sion. Coupling of the optogenetic interven-
tion to ongoing activity dynamics in vivo 
through the use of miniature imaging and 
other recording devices and closed-loop, 
on-demand systems can also be expected to 
have a transformative impact. Taking it a step 
BRAIN initiative. Looking back on the tools 
developed over the past decade, it was clear 
that the field was ready for a major leap for-
ward. This is a great example of the ‘then, 
now, imagine’ approach to launching scien-
tific programs. One slightly simplistic mis-
sion of the BRAIN initiative is to imagine we 
had the tools for human neuroscience that 
we have today for mice. In reality, the need 
to deliver an engineered channel and a light 
source will make optogenetics a tough reach 
for deep brain stimulation. But an artificial 
retina, a prosthetic for a cortical pacemaker 
or another form of chemogenomics (such as 
designer receptors) are all worth consider-
ing for human application. Seeing what this 
tool has done for studies in mice, optogenet-
ics should persuade clinical neuroscientists to 
‘think different’.
Antonello Bonci: This is the most extraor-
dinary part about optogenetics, which I 
consider the best tool that my laboratory 
has to develop treatments for certain human 
diseases such as substance use disorders. I 
personally love its intellectual and technical 
proximity to therapeutic treatments that have 
been employed for many years with limited, 
narrow therapeutic indications. I am refer-
ring to brain stimulation techniques such as 
repetitive Transcranial Magnetic Stimulation 
(rTMS) and DBS. While the core features of 
DBS, rTMS and optogenetics differ substan-
tially, they share a similar strength: alter-
ing electrical activity in brain regions and 
pathways in order to ameliorate behavioral 
symptoms. A concrete proof of my enthusi-
asm comes from a paper that my group pub-
lished in Nature back in 2013 (Chen, B.T. et al. 
Nature 496, 359–362 (2013)). In this study, we 
first showed a marked reduction in prefron-
tal cortex excitability in compulsive cocaine-
seeking rats. We then used in vivo optogenetic 
prelimbic cortex stimulation and observed 
decreases compulsive drug-seeking behav-
iors. When I started presenting this data, it 
immediately caught the attention of clinicians. 
As early as July 2013, the first treatment-
seeking patients were already volunteering 
to be treated with rTMS stimulation of their 
frontal cortex, and our initial results, while 
preliminary (this first study is being submit-
ted as we speak), are remarkably promising. 
I also find truly extraordinary the fact that, 
instead of having to wait 15 years to develop 
a drug target, fellow clinicians could get an 
optogenetic-based experimental treatment to 
patients in a matter of months. Given that we 
have no treatment for cocaine use disorders 
yet, I find this opportunity truly promising. 
rTMS has been around for a very long time, 
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